UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) |
(Zip Code) |
(
Registrant’s telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|||
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.02. Termination of a Material Definitive Agreement.
As previously disclosed, on May 7, 2020, Albireo Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) with respect to an “at-the-market” offering program under which the Company could offer and sell, from time to time at the Company’s sole discretion, shares of its common stock having an aggregate offering price of up to $50 million, through Cowen as its sales agent.
On September 9, 2020, the Company delivered written notice to Cowen to terminate the Sales Agreement pursuant to Section 11(b) thereof, which the parties agreed to make immediately effective.
A copy of the Sales Agreement was filed as Exhibit 1.2 to the Company’s Registration Statement on Form S-3, filed with the Securities and Exchange Commission on May 7, 2020.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALBIREO PHARMA, INC. | |
Date: September 9, 2020 | /s/ Ronald H.W. Cooper |
Ronald H.W. Cooper | |
President and Chief Executive Officer |
Cover |
Sep. 09, 2020 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Sep. 09, 2020 |
Entity File Number | 001-33451 |
Entity Registrant Name | ALBIREO PHARMA, INC. |
Entity Central Index Key | 0001322505 |
Entity Tax Identification Number | 90-0136863 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 10 Post Office Square |
Entity Address, Address Line Two | Suite 1000 |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02109 |
City Area Code | 857 |
Local Phone Number | 254-5555 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | ALBO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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
%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N M:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;: X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L5 M3,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I" M)\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF M"=9#;E9T!N[RZ .; O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( -*"*5$D'INBK0 /@! M : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U M4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL& MRF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*/Y#='7= M:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04 " #2@BE199!YDAD! M #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8 MH*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0= M47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEX MZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1 M=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN# MOI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 M Q0 ( -*"*5$'04UB@0 +$ 0 " 0 !D;V-0 M &UL4$L! A0#% @ TH(I40+BU;;N *P( !$ M ( !KP &1O8U!R;W!S+V-O &UL4$L! A0#% @ TH(I M49E &PO=V]R:W-H965T &UL4$L! A0#% @ TH(I M48.II0/4 0 ,@8 T ( !@ P 'AL+W-T>6QE &PO=V]R:V)O;VLN>&UL4$L! A0#% @ TH(I420> MFZ*M ^ $ !H ( !R! 'AL+U]R96QS+W=O 9(9 0 SP, !, M ( !K1$ %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ &]Q( end
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end